Evidence map›Paper›PMID 19198625›Full record

ArticleOncogene2009

15-LOX-1 transcription suppression through the NuRD complex in colon cancer cells.

X Zuo, J S Morris, R Broaddus, I Shureiqi

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Epigenetic regulation of 15-lipoxygenase-1 expression in human chondrocytes by promoter methylation.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023
    Article
  2. Ferroptosis Involvement in Glioblastoma Treatment.Medicina (Kaunas, Lithuania) · 2022
    Review
  3. Review
  4. Article
  5. Targeting Lipid Peroxidation for Cancer Treatment.Molecules (Basel, Switzerland) · 2020
    Review
  6. Review
  7. ALOX15 as a suppressor of inflammation and cancer: Lost in the link.Prostaglandins & other lipid mediators · 2017
    Review
  8. Article
  9. Review
  10. Review
  11. Eicosanoid pathway in colorectal cancer: Recent updates.World journal of gastroenterology · 2015
    Review
  12. Induction of apoptosis by Trichostatin A in human breast cancer cell lines: involvement of 15-Lox-1.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013
    Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

X ZuoDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
J S Morris
R Broaddus
I Shureiqi
The University of Texas MD Anderson Cancer Center · US

Funding

5-LOX-1 and Clinical Chemoprevention of Colon TumorsR01CA106577 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHUREIQI, IMAD · 2005 to 2008
$1.3M
Molecular Targeting of 15-Lipoxygenase-1 in Colon CancerR01CA104278 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHUREIQI, IMAD · 2004 to 2007
$1.0M
NCI NIH HHS R01 CA104278NCI NIH HHS R01 CA106577
6 · The paper itself

Abstract

15-Lipoxygenase-1 (15-LOX-1) is transcriptionally silenced in cancer cells, and its transcription reactivation (for example, through histone deacetylase inhibitors (HDACIs)) restores apoptosis to cancer cells. However, the exact mechanism underlying 15-LOX-1 transcription reactivation in cancer cells is still undefined. Therefore, we evaluated the critical mechanisms required for 15-LOX-1 transcription reactivation in colon cancer cells. Specific HDAC1 and HDAC2 inhibition activated 15-LOX-1 transcription. 15-LOX-1 transcription was repressed through transcription repressor complex recruitment in the region of -120 to -391 of the 15-LOX-1 promoter. The nucleosome remodeling and histone deacetylase (NuRD) repression complex was recruited to this region. Depsipeptide significantly reduced the recruitment of NuRD key components (for example, metastasis-associated protein 1 (MTA1) and HDAC1) to the 15-LOX-1 promoter before 15-LOX-1 transcriptional activation. Knock down of NuRD key components (for example, MTA1 and HDAC1) by small interfering RNA (siRNA) activated 15-LOX-1 transcription, as measured by luciferase reporter assays in stably transfected SW480 cells with the 15-LOX-1 promoter construct of the -391, but not the -120 region. Relative to expression in normal tissue, MTA1 expression in colorectal cancer mucosa from colorectal cancer patients was negatively related to 15-LOX-1 expression. Thus, our results show that NuRD contributes to 15-LOX-1 transcription suppression in colon cancer cells and that HDACIs can inhibit NuRD recruitment to a promoter to activate gene transcription, as in the case of 15-LOX-1.

Indexed as

AgedAged, 80 and overArachidonate 15-LipoxygenaseCell Line, TumorColonic NeoplasmsFemaleHistone Deacetylase 1Histone Deacetylase 2Histone Deacetylase InhibitorsHistone DeacetylasesHumansMaleMi-2 Nucleosome Remodeling and Deacetylase ComplexMiddle AgedPromoter Regions, GeneticRepressor ProteinsArachidonate 15-LipoxygenaseHDAC1 protein, humanHistone Deacetylase 1Histone Deacetylase 2Histone Deacetylase InhibitorsHistone DeacetylasesMi-2 Nucleosome Remodeling and Deacetylase ComplexMTA1 protein, humanRepressor ProteinsTrans-Activators

Identifiers

PMID19198625
PMCPMC2743348
OpenAlexW1984793393

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.